dpp 4 inhibitors vs glp 1 GLP-1 analogues and DPP-4 in type 2 diabetes therapy: from structural biology to clinics DPP-4 inhibitors and GLP-1RAs: cardiovascular

01.03.25 January report showed uptick in MDL actions Plaintiffs continued to file GLP-1 lawsuits, increasing the total number of claims to 1,331

Wegovy is a medication that significantly impacts the gastrointestinal tract and directly communicates with the appetite centre in the brain, the hypothalamus

At the level of the vascular smooth muscle cells, they protect against pathogenic, proliferative remodeling of the vascular smooth muscle cells, thus delaying plaque formation and stabilizing existing lesions

Diabet Med 2008;25:442-9.ArticlePubMedPMC 430

Comparison of steps in manual prior authorization vs electronic prior authorization (ePA) processes for GLP-1 prescriptions

In mid-2025, Aetna announced that some plans would no longer cover Zepbound